The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has published an expert consensus position paper on conducting clinical trials in HF during and after the COVID-19 pandemic.

A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Survival was examined in a cohort of hospitalized COVID-19 patients in New York City, who were divided in those who received anticoagulation during hospital stay and those who did not.

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

In a letter to the editor, Baldi and colleagues describe a study on the incidence of out-of-hospital cardiac arrest in 4 provinces in Lombardy, Italy, during the initial outbreak of COVID-19.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

COVID-19 can lead to systemic coagulation activation and thrombotic complications. Prof. Middeldorp describes the results of a study investigating the incidence of VTE in hospitalized COVID-19 patients.

A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.